Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT02757066 Completed - Clinical trials for Autism Spectrum Disorder

Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders

NPC-15-5
Start date: June 16, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to verify the efficacy of NPC-15 (melatonin 1 mg/d or 4 mg/d) versus placebo to sleep latency with electronic sleep diaries.

NCT ID: NCT02756507 Completed - Clinical trials for Generalized Anxiety Disorder

Transdiagnostic REBT Prevention Program for Adolescents

Start date: June 2016
Phase: N/A
Study type: Interventional

Anxiety and depressive disorders are common in adolescents, however they are often unrecognized. Rational emotive behavioral therapy (REBT), a form of cognitive behavioral therapy (CBT) is efficient for children and adolescents. School settings are appropriate environments to deliver such interventions for vulnerable youths. Given youth's access and predilection to use technology, a video-based prevention program was developed. The present study aims to investigate the efficacy of a transdiagnostic REBT prevention program for internalizing symptoms in adolescents, implemented in a school setting. Classes from different Romanian public schools will be randomized in either intervention or wait list group.

NCT ID: NCT02755181 Completed - Clinical trials for Borderline Personality Disorder

fMRI in Impulsivity

Start date: July 22, 2016
Phase:
Study type: Observational

This study aims to use resting-state and task based functional Magnetic Resonance Imaging (fMRI) as a tool to evaluate trait characteristics of impulsivity in subjects with borderline personality disorder.

NCT ID: NCT02755103 Completed - Clinical trials for Substance-Related Disorders

Mindfulness Meditation for the Treatment of Women With Comorbid PTSD and SUD

Start date: June 1, 2016
Phase: N/A
Study type: Interventional

The current study will modify an already existing therapy for individuals with substance use disorders to address Post Traumatic Stress Disorder (PTSD) in women enrolled in substance use disorders (SUD) treatment who suffer with both PTSD and SUD. Mindfulness meditation has been shown to help individuals to cope with stress and regulate emotions. Through meditation practice women will experience less distress related to PTSD symptoms and reduced substance use in response to emotional triggers. Women enrolled in intensive SUD treatment at a community program will be randomized to receive either 8 weeks of 90 minute Mindfulness Based Relapse Prevention (MBRP) group sessions plus treatment as usual (TAU) or TAU alone. The MBRP group sessions will replace 90 minutes of TAU group therapy. Measures of feasibility of implementation, acceptance and adherence will be obtained. Preliminary efficacy for substance use and PTSD symptom severity will be measured at post treatment and at 3- and 6- months' follow-up.

NCT ID: NCT02755051 Completed - Clinical trials for Autism Spectrum Disorder

Targeting Sleep in Kids With Autism Spectrum Disorder

Start date: July 2016
Phase: N/A
Study type: Interventional

Children with Autism Spectrum Disorder (ASD) and insomnia, and their parent(s) will undergo 8 sessions of Cognitive Behavioral Therapy designed for Children with Chronic Insomnia and ASD (CBT-CI-A). Treatment delivery will be assessed for each session. Treatment receipt will be assessed at the end of session 3. Treatment enactment will be assessed throughout treatment, post-treatment, and follow-up. Sleep and secondary outcomes (child daytime behavior, parent sleep) will be collected at baseline, post-treatment, and 1-month follow-up. Study Flow: Baseline (wk1-2) ---> CBT-CI-A (wk3-10) ---> Post-Treatment (wk11-12) --->Wks 13-16 --->Follow-up (wk 17-18) Session: 1. Sleep education 2. Sleep scheduling, limit setting, and stimulus control 3. Teaching relaxation strategies and other adaptive coping skills 4. Parenting strategies (differential attention, rewards, consequences) 5. Identification of maladaptive & adaptive cognitions 6. Problem solving & communication skills 7. Sleep restriction; bright light to change circadian rhythms 8. Review gains and plan for long-term maintenance

NCT ID: NCT02752542 Recruiting - Clinical trials for Major Depressive Disorder

Personalized Indications for CBT and Antidepressants in Treating Depression

CANBIND6
Start date: October 31, 2016
Phase: Phase 4
Study type: Interventional

Depression currently affects close to 2 million Canadians and is the leading cause of disability worldwide. Pharmacological treatments (antidepressant medication) and psychological treatments such as cognitive-behavioural therapy are available for depression, but the majority of those who receive treatment have an unsatisfactory response. On average, the combination of pharmacological and psychological treatment achieves better results than either treatment alone. However, the apparently superior results of combination treatment may be due to the fact that different individuals preferentially respond to pharmacological or psychological treatment. The invesitagtors have discovered several clinical factors and biomarkers that predict poor response to commonly used antidepressant medication: history of childhood maltreatment, loss of interest and reduced activity, a biomarker of systemic inflammation, and a genetic marker of sensitivity to environment. Indirect evidence suggests that the same factors may indicate the need for psychological treatment, but their usefulness as differential predictors of psychological and pharmacological treatment outcomes remains to be established. The investigators will test the hypothesis that a pre-determined set of clinical variables (history of childhood maltreatment, loss of interest and reduced activity) and biomarkers (serum C-reactive protein, a marker of systemic inflammation, and short alleles of the serotonin transporter gene promoter polymorphism) differentially predicts response to antidepressants and to cognitive-behavioural psychotherapy with clinically significant accuracy. If this hypothesis is supported, the resulting predictor will allow personalized selection of treatment for depression, leading to improved outcomes and healthcare efficiency. Additional objectives include replication of additional predictors and integrative analyses aimed at refining the treatment choice algorithms.

NCT ID: NCT02752503 Recruiting - Clinical trials for Alcohol Use Disorder

Nalmefene in Alcohol Dependence and Borderline Personality Disorder

Start date: March 2015
Phase: N/A
Study type: Interventional

The objective is to study the effectiveness of Nalmefene in decreasing alcohol intake in subjects with alcohol use disorder and comorbid BPD.

NCT ID: NCT02752295 Completed - Inflammation Clinical Trials

Intensive Stress Coping Intervention Week - A Secondary Prevention For Real World Affective Disorder Patients

ISCIW
Start date: May 2015
Phase: N/A
Study type: Interventional

This study intents to determine who will benefit from an intensive brief stress coping intervention week (ISCIW) as secondary prevention for real world affective disorder patients.

NCT ID: NCT02752139 Completed - Clinical trials for Sleep Disorders, Intrinsic

Cerebral Hemodynamics in Sleep Disorders

Start date: May 2016
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to determine the relationship between sleep disorders and cerebral hemodynamics.

NCT ID: NCT02751632 Active, not recruiting - Psychotic Disorders Clinical Trials

The Staged Treatment in Early Psychosis Study

STEP
Start date: April 2016
Phase: Phase 3
Study type: Interventional

A sequential multistage randomised clinical trial (SMART) to produce evidence to guide a step-wise clinical approach for the treatment of ultra high risk patients and reduction of risk for psychosis and other deleterious clinical and/or functional outcomes.